Herein, we found that c-Met expression is significantly upregulated in osimertinib-resistant NSCLC cells, and knockdown of c-Met resulted in a significant decrease in tumorigenicity both in vitro and in vivo, with a significant extension in the survival period of tumor-bearing mice with c-Met downregulation. This evidence concerns the gene MET and non-small cell lung carcinoma.